JP2017528117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528117A5 JP2017528117A5 JP2016575026A JP2016575026A JP2017528117A5 JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5 JP 2016575026 A JP2016575026 A JP 2016575026A JP 2016575026 A JP2016575026 A JP 2016575026A JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- multispecific antibody
- molecule according
- domain
- dsfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1411420.1 | 2014-06-26 | ||
| GBGB1411420.1A GB201411420D0 (en) | 2014-06-26 | 2014-06-26 | Antibody constructs |
| PCT/EP2015/064450 WO2015197789A1 (en) | 2014-06-26 | 2015-06-25 | Multi-specific antibody constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528117A JP2017528117A (ja) | 2017-09-28 |
| JP2017528117A5 true JP2017528117A5 (enExample) | 2018-08-02 |
Family
ID=51410201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575026A Pending JP2017528117A (ja) | 2014-06-26 | 2015-06-25 | 多重特異性抗体コンストラクト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170198062A1 (enExample) |
| EP (1) | EP3161008B1 (enExample) |
| JP (1) | JP2017528117A (enExample) |
| CN (1) | CN106459217A (enExample) |
| BR (1) | BR112016030424A2 (enExample) |
| CA (1) | CA2953638A1 (enExample) |
| ES (1) | ES2763525T3 (enExample) |
| GB (1) | GB201411420D0 (enExample) |
| RU (1) | RU2710730C2 (enExample) |
| WO (1) | WO2015197789A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012307157B2 (en) * | 2011-09-16 | 2017-08-03 | Ucb Pharma S.A. | Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| CN110770255B (zh) | 2017-04-11 | 2025-07-01 | 因荷布瑞克斯生物科学公司 | 具有受限cd3结合的多特异性多肽构建体及其使用方法 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| AU2019205406A1 (en) * | 2018-01-08 | 2020-08-27 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| SG11202009804RA (en) | 2018-04-11 | 2020-11-27 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| TW202028245A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | Dll3單域抗體及其治療性組合物 |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| MX2022010915A (es) * | 2020-03-03 | 2022-10-07 | Systimmune Inc | Anticuerpos anti-cd19, metodos de uso y fabricacion de los mismos. |
| JP2023519576A (ja) | 2020-03-27 | 2023-05-11 | ユーシービー バイオファルマ エスアールエル | 自律ノブドメインペプチド |
| IL303295A (en) | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2246538C2 (ru) * | 1998-05-20 | 2005-02-20 | Чугаи Сейяку Кабусики Кайся | Способ и набор для выявления гена, кодирующего мембраносвязанный белок, вектор (варианты) |
| AR056142A1 (es) * | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| CN101842387B (zh) * | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| WO2010027981A1 (en) * | 2008-09-03 | 2010-03-11 | Genentech, Inc. | Multispecific antibodies |
| WO2010034441A1 (en) * | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
| SG177560A1 (en) * | 2009-07-06 | 2012-03-29 | Hoffmann La Roche | Bi-specific digoxigenin binding antibodies |
| WO2012025530A1 (en) * | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| JP6273219B2 (ja) * | 2012-03-13 | 2018-01-31 | ノビミューン エスアー | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
-
2014
- 2014-06-26 GB GBGB1411420.1A patent/GB201411420D0/en not_active Ceased
-
2015
- 2015-06-25 BR BR112016030424A patent/BR112016030424A2/pt not_active Application Discontinuation
- 2015-06-25 CA CA2953638A patent/CA2953638A1/en not_active Abandoned
- 2015-06-25 US US15/321,061 patent/US20170198062A1/en not_active Abandoned
- 2015-06-25 EP EP15733415.2A patent/EP3161008B1/en active Active
- 2015-06-25 JP JP2016575026A patent/JP2017528117A/ja active Pending
- 2015-06-25 ES ES15733415T patent/ES2763525T3/es active Active
- 2015-06-25 WO PCT/EP2015/064450 patent/WO2015197789A1/en not_active Ceased
- 2015-06-25 RU RU2017102312A patent/RU2710730C2/ru active
- 2015-06-25 CN CN201580034555.0A patent/CN106459217A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528117A5 (enExample) | ||
| RU2017102312A (ru) | Конструкции мультиспецифичных антител | |
| RU2017102193A (ru) | Конструкции полиспецифических антител | |
| JP2019506841A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2018127467A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2016521688A5 (enExample) | ||
| JP2020503001A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2016185981A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| JP2018527919A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2019534277A5 (enExample) | ||
| JP2016529215A5 (enExample) | ||
| HRP20220111T1 (hr) | Protutijela protiv pd-1 | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| HRP20240495T1 (hr) | Anti-garp antitijelo | |
| EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
| JP2017530722A5 (enExample) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |